Sanofi-Aventis (Canada)

74 articles with Sanofi-Aventis (Canada)

• Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

  3/21/2023

  sanofi-aventis Canada Inc. is pleased to announce that Health Canada has issued a Notice of Compliance for Rezurock™, for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

• Canadians Encouraged to Live "In Range" to Better Manage their Diabetes

  10/26/2022

  Soon after the onset of the COVID-19 pandemic, it became increasingly evident that necessary infection control measures also had unintended consequences for Canadians living with diabetes.

• Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon

  6/14/2022

  Since the onset of the COVID-19 pandemic, diabetes care has been significantly impacted by the reduction in access to healthcare programs and services, resulting in a majority of people with diabetes experiencing mental health problems.

• Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation

  3/28/2022

  Today sanofi-aventis Canada Inc. (Sanofi Canada) announced the expanded approval of Dupixent® (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.

• Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer

  3/25/2022

  sanofi-aventis Canada Inc. announced the approval of Libtayo® for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease.

• Competition Bureau completes abuse of dominance investigation into practices of Celgene, Pfizer and Sanofi

  12/20/2018

  The Competition Bureau announced today that it is closing an investigation into allegations of abuse of dominance by certain brand name drug manufacturers including Celgene Inc., Pfizer Canada Inc. and Sanofi-Aventis Canada Inc.

• Dr. Hitto Kaufmann of Sanofi-Aventis and Dr. Eliana Clark of Biogen to Deliver Plenary Keynote Presentations at CHI's Bioprocessing Summit Europe

  12/12/2017

  These presentations will explore next-gen bioprocess strategies, pipelines and facilities.

• Sanofi-Aventis (Canada) Healthcare Survey Explores The Workplace's Impact On Health

  6/15/2016

• Health Canada Release: Advisory - Two Lots Of Sanofi-Aventis (Canada)'s Allerject (0.15 Mg / 0.15ml Auto-Injector) For Use In Children Recalled Due To Manufacturing Defect

  6/15/2015

• Sanofi-Aventis (Canada) Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research

  4/18/2011

• Sanofi-Aventis (Canada) to Acquire Canderm Pharma Inc., a Leading Canadian Skin Care Company

  6/16/2010

• Sanofi-Aventis (Canada) Transforms to Support Sustainable Business Model; 70 Jobs Cut in Process

  5/5/2010

• Sanofi-Aventis (Canada) Appoints Hugh O'Neill as President and CEO

  9/16/2009

• Health Canada Approves Sanofi-Aventis (Canada)'s Multaq(TM) for Patients with Atrial Fibrillation

  8/12/2009

• Sanofi-Aventis (Canada) Licenses I-many ContractSphere to Manage Complex Pharmaceutical Contracts

  1/8/2009

• Winston Laboratories, Inc. Announces Licensing Agreement With Sanofi-Aventis (Canada). in Canada

  11/7/2008

• Sanofi-Aventis (France)'s Acomplia Linked To 5 Deaths

  6/4/2008

• Sanofi-Aventis (Canada) Celebrates the Completion of Construction Projects at its Canadian Headquarters Representing an Investment of $25 Million

  5/20/2008

• Desperate But Not Crazy

  12/20/2007

• Sanofi-Aventis (Canada) Release: Health Canada Approves New Chemotherapy Treatment for Patients with Metastatic Colorectal Cancer

  6/18/2007